Immunotherapy in chronic lymphocytic leukemia: advances and challenges
Abstract Chronic lymphocytic leukemia (CLL) is characterized as a clonal proliferation of mature B lymphocytes with distinct immunophenotypic traits, predominantly affecting the middle-aged and elderly population. This condition is marked by an accumulation of lymphocytes within the peripheral blood...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40164-025-00644-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849726377477013504 |
|---|---|
| author | Pan Gao Yang Zhang Jun Ma Ya Zhang |
| author_facet | Pan Gao Yang Zhang Jun Ma Ya Zhang |
| author_sort | Pan Gao |
| collection | DOAJ |
| description | Abstract Chronic lymphocytic leukemia (CLL) is characterized as a clonal proliferation of mature B lymphocytes with distinct immunophenotypic traits, predominantly affecting the middle-aged and elderly population. This condition is marked by an accumulation of lymphocytes within the peripheral blood, bone marrow, spleen, and lymph nodes. The associated immune dysregulation predisposes CLL patients to a higher risk of secondary malignancies and infections, which significantly contribute to morbidity and mortality rates. The advent of immunotherapy has revolutionized the prognosis of CLL, advancing treatment modalities and offering substantial benefits to patient outcomes. This review endeavors to synthesize and scrutinize the efficacy, merits, and limitations of the current immunotherapeutic strategies for CLL. The aim is to inform the selection of optimal treatment regimens tailored to individual patient needs. Furthermore, the review juxtaposes various therapeutic combinations to elucidate the comparative advantages of each approach, with the ultimate objective of enhancing patient prognosis and quality of life. |
| format | Article |
| id | doaj-art-e21db9a504bb43df938d3116451b0f5e |
| institution | DOAJ |
| issn | 2162-3619 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Experimental Hematology & Oncology |
| spelling | doaj-art-e21db9a504bb43df938d3116451b0f5e2025-08-20T03:10:11ZengBMCExperimental Hematology & Oncology2162-36192025-04-0114112410.1186/s40164-025-00644-5Immunotherapy in chronic lymphocytic leukemia: advances and challengesPan Gao0Yang Zhang1Jun Ma2Ya Zhang3Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityAbstract Chronic lymphocytic leukemia (CLL) is characterized as a clonal proliferation of mature B lymphocytes with distinct immunophenotypic traits, predominantly affecting the middle-aged and elderly population. This condition is marked by an accumulation of lymphocytes within the peripheral blood, bone marrow, spleen, and lymph nodes. The associated immune dysregulation predisposes CLL patients to a higher risk of secondary malignancies and infections, which significantly contribute to morbidity and mortality rates. The advent of immunotherapy has revolutionized the prognosis of CLL, advancing treatment modalities and offering substantial benefits to patient outcomes. This review endeavors to synthesize and scrutinize the efficacy, merits, and limitations of the current immunotherapeutic strategies for CLL. The aim is to inform the selection of optimal treatment regimens tailored to individual patient needs. Furthermore, the review juxtaposes various therapeutic combinations to elucidate the comparative advantages of each approach, with the ultimate objective of enhancing patient prognosis and quality of life.https://doi.org/10.1186/s40164-025-00644-5Chronic lymphocytic leukemiaImmunotherapyAntibodyImmune cellCombination therapy |
| spellingShingle | Pan Gao Yang Zhang Jun Ma Ya Zhang Immunotherapy in chronic lymphocytic leukemia: advances and challenges Experimental Hematology & Oncology Chronic lymphocytic leukemia Immunotherapy Antibody Immune cell Combination therapy |
| title | Immunotherapy in chronic lymphocytic leukemia: advances and challenges |
| title_full | Immunotherapy in chronic lymphocytic leukemia: advances and challenges |
| title_fullStr | Immunotherapy in chronic lymphocytic leukemia: advances and challenges |
| title_full_unstemmed | Immunotherapy in chronic lymphocytic leukemia: advances and challenges |
| title_short | Immunotherapy in chronic lymphocytic leukemia: advances and challenges |
| title_sort | immunotherapy in chronic lymphocytic leukemia advances and challenges |
| topic | Chronic lymphocytic leukemia Immunotherapy Antibody Immune cell Combination therapy |
| url | https://doi.org/10.1186/s40164-025-00644-5 |
| work_keys_str_mv | AT pangao immunotherapyinchroniclymphocyticleukemiaadvancesandchallenges AT yangzhang immunotherapyinchroniclymphocyticleukemiaadvancesandchallenges AT junma immunotherapyinchroniclymphocyticleukemiaadvancesandchallenges AT yazhang immunotherapyinchroniclymphocyticleukemiaadvancesandchallenges |